Welcure Drugs and Pharmaceuticals Ltd
BSE:524661
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Welcure Drugs and Pharmaceuticals Ltd
BSE:524661
|
IN |
|
Aurora Solar Technologies Inc
XTSX:ACU
|
CA |
|
Regis Resources Ltd
ASX:RRL
|
AU |
Cash Flow Statement
Cash Flow Statement
Welcure Drugs and Pharmaceuticals Ltd
| Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
1
|
(0)
|
0
|
0
|
1
|
(0)
|
(2)
|
14
|
28
|
438
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Non-Cash Items |
0
|
0
|
0
|
0
|
0
|
3
|
0
|
(0)
|
0
|
0
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
(0)
|
(0)
|
(0)
|
1
|
0
|
(0)
|
0
|
(1 002)
|
(2 248)
|
(1 671)
|
|
| Cash from Operating Activities |
0
N/A
|
(0)
N/A
|
0
N/A
|
1
+622%
|
1
-20%
|
2
+133%
|
(1)
N/A
|
(991)
-77 590%
|
(2 220)
-124%
|
(1 233)
+44%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
|
| Other Items |
0
|
0
|
0
|
0
|
13
|
12
|
2
|
2
|
(0)
|
0
|
|
| Cash from Investing Activities |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
13
N/A
|
12
-11%
|
2
-86%
|
2
+36%
|
(1)
N/A
|
0
N/A
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
990
|
990
|
0
|
|
| Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 232
|
0
|
|
| Other |
0
|
0
|
0
|
13
|
(15)
|
(28)
|
(0)
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
0
N/A
|
0
N/A
|
0
N/A
|
13
N/A
|
(15)
N/A
|
(28)
-91%
|
(0)
+99%
|
990
N/A
|
2 222
+124%
|
1 232
-45%
|
|
| Change in Cash | |||||||||||
| Net Change in Cash |
0
N/A
|
(0)
N/A
|
0
N/A
|
15
+7 740%
|
(1)
N/A
|
(14)
-2 098%
|
0
N/A
|
2
+816%
|
1
-43%
|
(1)
N/A
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
0
N/A
|
(0)
N/A
|
0
N/A
|
1
+622%
|
1
-20%
|
2
+133%
|
(1)
N/A
|
(991)
-77 590%
|
(2 220)
-124%
|
(1 233)
+44%
|
|